{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:54:24Z","timestamp":1786982064801,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008252","name":"Universit\u00e0 degli Studi di Udine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glucocorticoids (GCs) are still the mainstay of treatment of giant cell arteritis (GCA). Although GCs are highly effective in GCA, the high burden of toxicity of GCs as well as the disease relapse during GC tapering is well documented. To compare the efficacy and rapidity of TCZ and MTX as steroid-sparing agents in a real-life cohort of GCA patients. A retrospective analysis was conducted including patients with newly diagnosed GCA from the Rheumatology Units of Udine and Rome. The inclusion criterion was the treatment with TCZ or MTX as first steroid-sparing drug. 112 GCA patients (81 females) with a median age of 70 (IQ 65\u201375) years were collected. Thirty-one out of 112 (27.7%) patients were treated with TCZ (162\u00a0mg\/week), while 81\/112 (72.3%) patients received MTX (up to 20\u00a0mg\/week) as a GC-sparing agent. At month 6 after GCA onset, 5\/31 (16.1%) patients in TCZ group and none in MTX group were in GC-free sustained remission (\n                    <jats:italic>p<\/jats:italic>\n                    value\u2009=\u20090.001). Similarly, at month 12, 64.5% (20\/31) and 11.1% (9\/81) of patients were in sustained GC-free remission in TCZ and MTX group, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    value &lt;0.001). At month 24 of follow-up, at least one relapse of the disease occurred in 7\/31 (22.6%) in TCZ-treated and 28\/81 (34.6%) in MTX-treated patients, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    value\u2009=\u20090.22). TCZ allowed a faster discontinuation of steroid therapy than MTX in GCA patients, without increasing the risk of relapse.\n                  <\/jats:p>","DOI":"10.1007\/s11739-024-03722-4","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:40:09Z","timestamp":1722591609000},"page":"2177-2184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-6439","authenticated-orcid":false,"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Treppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"3722_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"3722_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12016-008-8075-0","volume":"35","author":"JL Lee","year":"2008","unstructured":"Lee JL, Naguwa SM, Cheema GS, Gershwin ME (2008) The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol 35:88\u201395. https:\/\/doi.org\/10.1007\/s12016-008-8075-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"3722_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/rheumatology\/kew273","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F et al (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 56:506\u2013515. https:\/\/doi.org\/10.1093\/rheumatology\/kew273","journal-title":"Rheumatology"},{"key":"3722_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S et al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19\u201330. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672","journal-title":"Ann Rheum Dis"},{"key":"3722_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/1358863X19886074","volume":"25","author":"F Valent","year":"2019","unstructured":"Valent F, Bond M, Cavallaro E et al (2019) Data linkage analysis of giant cell arteritis in Italy: healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001\u20132017). Vasc Med 25:150\u2013156. https:\/\/doi.org\/10.1177\/1358863X19886074","journal-title":"Vasc Med"},{"key":"3722_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100072","volume":"3","author":"L Quartuccio","year":"2020","unstructured":"Quartuccio L, Isola M, Bruno D et al (2020) Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: a multicenter retrospective controlled study. J Transl Autoimmun 3:100072. https:\/\/doi.org\/10.1016\/j.jtauto.2020.100072","journal-title":"J Transl Autoimmun"},{"key":"3722_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"3722_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/rheumatology\/kes127","volume":"51","author":"L Quartuccio","year":"2012","unstructured":"Quartuccio L, Maset M, De Maglio G et al (2012) Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology 51:1677\u20131686. https:\/\/doi.org\/10.1093\/rheumatology\/kes127","journal-title":"Rheumatology"},{"key":"3722_CR9","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jgs.14004","volume":"64","author":"A Carbonella","year":"2016","unstructured":"Carbonella A, Berardi G, Petricca L et al (2016) Immunosuppressive therapy (methotrexate or cyclophosphamide) in combination with corticosteroids in the treatment of giant cell arteritis: comparison with corticosteroids alone. J Am Geriatr Soc 64:672\u2013374. https:\/\/doi.org\/10.1111\/jgs.14004","journal-title":"J Am Geriatr Soc"},{"key":"3722_CR10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/rheumatology\/keac697","volume":"62","author":"L Quartuccio","year":"2022","unstructured":"Quartuccio L, Treppo E, Dejaco C (2022) The pre-clinical phase of giant cell arteritis: new clues in the pathogenesis of giant cell arteritis supporting emerging targets. Rheumatology 62:2032\u20132034. https:\/\/doi.org\/10.1093\/rheumatology\/keac697","journal-title":"Rheumatology"},{"key":"3722_CR11","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/jcm11071799","volume":"11","author":"A R\u00e9gent","year":"2022","unstructured":"R\u00e9gent A, Mouthon L (2022) Treatment of giant cell arteritis (GCA). J Clin Med 11:1799. https:\/\/doi.org\/10.3390\/jcm11071799","journal-title":"J Clin Med"},{"key":"3722_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.732934","volume":"8","author":"A Mahr","year":"2021","unstructured":"Mahr A, Hachulla E, de Boysson H et al (2021) Presentation and real-world management of giant cell arteritis (Artemis Study). Front Med 8:732934. https:\/\/doi.org\/10.3389\/fmed.2021.732934","journal-title":"Front Med"},{"key":"3722_CR13","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/jcm10132948","volume":"10","author":"K Izumi","year":"2021","unstructured":"Izumi K, Murata O, Higashida-Konishi M et al (2021) Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study. J Clin Med 10:2948. https:\/\/doi.org\/10.3390\/jcm10132948","journal-title":"J Clin Med"},{"key":"3722_CR14","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","volume":"60","author":"V Sch\u00f6nau","year":"2021","unstructured":"Sch\u00f6nau V, Roth J, Tascilar K et al (2021) Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatology 60:3851\u20133861. https:\/\/doi.org\/10.1093\/rheumatology\/keab332","journal-title":"Rheumatology"},{"key":"3722_CR15","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789\u20132797. https:\/\/doi.org\/10.1002\/art.22754","journal-title":"Arthritis Rheum"},{"key":"3722_CR16","first-page":"S86","volume":"31","author":"F Muratore","year":"2013","unstructured":"Muratore F, Pipitone N, Hunder GG, Salvarani C (2013) Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 31:S86\u2013S92","journal-title":"Clin Exp Rheumatol"},{"key":"3722_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3899\/jrheum.160249","volume":"44","author":"AJ Mohammad","year":"2017","unstructured":"Mohammad AJ, Englund M, Turesson C et al (2017) Rate of comorbidities in giant cell arteritis: a population-based study. J Rheumatol 44:84\u201390. https:\/\/doi.org\/10.3899\/jrheum.160249","journal-title":"J Rheumatol"},{"key":"3722_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s0049-0172(05)80029-0","volume":"22","author":"JD Adachi","year":"1993","unstructured":"Adachi JD, Bensen WG, Hodsman AB (1993) Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 22:375\u2013384. https:\/\/doi.org\/10.1016\/s0049-0172(05)80029-0","journal-title":"Semin Arthritis Rheum"},{"key":"3722_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A Proven","year":"2003","unstructured":"Proven A, Gabriel SE, Orces C et al (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49:703\u2013708. https:\/\/doi.org\/10.1002\/art.11388","journal-title":"Arthritis Rheum"},{"key":"3722_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/acr.23901","volume":"72","author":"S Mainbourg","year":"2020","unstructured":"Mainbourg S, Addario A, Samson M et al (2020) Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res 72:838\u2013849. https:\/\/doi.org\/10.1002\/acr.23901","journal-title":"Arthritis Care Res"},{"key":"3722_CR21","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/jcm11061588","volume":"11","author":"S Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda S, Prieto-Pe\u00f1a D, Vicente-Rabaneda EF et al (2022) Advances in the treatment of giant cell arteritis. J Clin Med 11:1588. https:\/\/doi.org\/10.3390\/jcm11061588","journal-title":"J Clin Med"},{"issue":"Suppl 111","key":"3722_CR22","first-page":"121","volume":"36","author":"L Leon","year":"2018","unstructured":"Leon L, Rodriguez-Rodriguez L, Morado I et al (2018) Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. Clin Exp Rheumatol 36(Suppl 111):121\u2013128","journal-title":"Clin Exp Rheumatol"},{"key":"3722_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3899\/jrheum.180429","volume":"46","author":"MJ Koster","year":"2019","unstructured":"Koster MJ, Yeruva K, Crowson CS et al (2019) Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol 46:501\u2013508. https:\/\/doi.org\/10.3899\/jrheum.180429","journal-title":"J Rheumatol"},{"key":"3722_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.semarthrit.2021.01.006","volume":"51","author":"M Calder\u00f3n-Goercke","year":"2021","unstructured":"Calder\u00f3n-Goercke M, Casta\u00f1eda S, Aldasoro V et al (2021) Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Semin Arthritis Rheum 51:387\u2013394. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.01.006","journal-title":"Semin Arthritis Rheum"},{"key":"3722_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-021-02529-4","volume":"23","author":"H de Boysson","year":"2021","unstructured":"de Boysson H, Le Besnerais M, Blaison F et al (2021) Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis. Arthritis Res Ther 23:143. https:\/\/doi.org\/10.1186\/s13075-021-02529-4","journal-title":"Arthritis Res Ther"},{"key":"3722_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","volume":"46","author":"MS Broder","year":"2016","unstructured":"Broder MS, Sarsour K, Chang E et al (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46:246\u2013252. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.009","journal-title":"Semin Arthritis Rheum"},{"key":"3722_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","volume":"58","author":"S Adler","year":"2019","unstructured":"Adler S, Reichenbach S, Gloor A et al (2019) Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology 58:1639\u20131643. https:\/\/doi.org\/10.1093\/rheumatology\/kez091","journal-title":"Rheumatology"},{"key":"3722_CR28","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/rheumatology\/keab780","volume":"61","author":"JH Stone","year":"2022","unstructured":"Stone JH, Spotswood H, Unizony SH et al (2022) New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology 61:2915\u20132922. https:\/\/doi.org\/10.1093\/rheumatology\/keab780","journal-title":"Rheumatology"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03722-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-024-03722-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-024-03722-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:08:43Z","timestamp":1732162123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-024-03722-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1007\/s11739-024-03722-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3547423\/v1","asserted-by":"object"}]},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors have approved the version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the procedures that contributed to this work complied with the ethical standards of the national and institutional committees responsible for human experimentation and the Declaration of Helsinki of 1975, revised in 2008. Patients signed an informed consent for the use of their data for research purposes. The study was approved by the Department of Medicine Institutional Review Board (IRB) (Prot. 169\/2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}